Clinical Cancer Investigation Journal

REVIEW ARTICLE
Year
: 2017  |  Volume : 6  |  Issue : 5  |  Page : 207--213

Mechanisms and biomarkers to detect chemotherapy-induced cardiotoxicity


Habib Haybar1, Mohammad Taha Jalali2, Kazem Zibara3, Zeinab Deris Zayeri4 
1 Department of Cardiology, Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2 Department of Biochemistry, Hyperlipidemia Research Center, Diabetes Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3 Department of Genetic, Clinical Research Development Unit, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4 Department of Biology, Laboratory of Stem Cells, DSST, Faculty of Sciences, Lebanese University, Beirut, Iran

Correspondence Address:
Zeinab Deris Zayeri
Golestan Hospital Clinical Research Development Unit, Ahvaz Jundishapur University of Medical Sciences, Ahvaz
Iran

A cardiotoxicity is a considerable event for cardiologists and oncologists during and after chemotherapy. The use of certain chemotherapy agents such as trastuzumab, programmed death-1 inhibitors, and Doxorubicin increased in cancer therapy; however, these agents associate with an increase in mortality and cardiotoxicity. Detecting cardiotoxicity is based on patient's medical history and physical examination since there is no exact biomarker or polymorphism for its early diagnosis. Therefore, we still need potential biomarkers for cardiotoxicity risk. Treatment of several cancers is manageable while preventing cardiotoxicity, as chemotherapy side effect, is essential since it might be a greater risk than the malignancy if not detected at early stages. Early detection of cardiotoxicity, during and after chemotherapy, is crucial to decrease permanent and devastating cardiac damages. Recently, troponin but also atrial-type and brain-type natriuretic peptides were reported as good diagnostic biomarkers for cardiotoxicity. Micro-RNAs and inflammatory mediators are candidates as prognostic biomarkers. Genetic biomarkers such as C282Y allele of hemochromatosis gene makes the patients more susceptible to cardiotoxicity; therefore, genome studies are valuable in predicting chemotherapy results. In this review, we present the mechanisms of developing chemotherapy-induced cardiotoxicity and biomarkers for its detection in patients. Echocardiographic techniques are very strong techniques which could be used along with biomarkers for more reliable and quicker diagnosis.


How to cite this article:
Haybar H, Jalali MT, Zibara K, Zayeri ZD. Mechanisms and biomarkers to detect chemotherapy-induced cardiotoxicity.Clin Cancer Investig J 2017;6:207-213


How to cite this URL:
Haybar H, Jalali MT, Zibara K, Zayeri ZD. Mechanisms and biomarkers to detect chemotherapy-induced cardiotoxicity. Clin Cancer Investig J [serial online] 2017 [cited 2017 Dec 18 ];6:207-213
Available from: http://www.ccij-online.org/article.asp?issn=2278-0513;year=2017;volume=6;issue=5;spage=207;epage=213;aulast=Haybar;type=0